Description: Anacalypsis Therapeutics is an early-stage biotech company discovering novel biomarkers and therapeutic strategies for neurodegenerative diseases. Parkinson’s disease is the fastest growing neurodegenerative disease, affecting approximately 10M people globally. In most neurodegenerative diseases, including Parkinson’s, there are no biomarkers for early detection or disease-modifying therapies that can disrupt the progression of the disease. This is compounded by the fact that by the time diagnosis is made, significant irreversible neurodegeneration has already occurred. Our approach to therapeutic development is the structure-based design of compounds that disrupt target pathway-specific signalling linked to neurodegeneration.